Treatment of ARDS With Instilled T3 (ARDS+T3)
PHASE II RANDOMIZED, INTERVENTION VERSUS NON- INTERVENTION, MULTI- CENTER STUDY OF THE EFFECTS OF THYROID HORMONE (T3) ON SAFETY/TOLERABILITY AND OXYGENATION IN SUBJECTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
Sponsor: University of Minnesota
This PHASE2 trial investigates ARDS, Human and Lung Inflammation and is currently actively recruiting participants. University of Minnesota leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Nov 2025 — Present [monthly]
Recruiting PHASE2
-
Nov 2024 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
▶ Show 6 earlier versions
-
Nov 2022 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2021 — Nov 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2019 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Minnesota
For direct contact, visit the study record on ClinicalTrials.gov .